Dr. Joel F. Schock IV, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 119
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
ND license 4892 · MN license 29157
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 119
- Services billed
- 9,558
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 167 | 103 |
| Established patient office or other outpatient visit, 30-39 minutes | 146 | 76 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 132 | 17 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 77 | 77 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 39 | 38 |
| Administration of influenza virus vaccine | 37 | 36 |
| Influenza vaccine split virus, preservative free | 33 | 32 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 27 |
| Aspiration and/or injection of fluid from large joint | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $16,461 in research payments for these studies, mostly to the institutions running them.
- M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
AbbVie Inc. · Active, not recruiting · NCT04524611 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.